Chronic kidney disease (CKD) has emerged as a major public health problems worldwide. It frequently progresses to end-stage renal disease which is related to very high cost and mortality. Novel biomarkers can provide insight into the novel mechanism, facilitate early detection and monitor progression of CKD and its response to therapeutic interventions. To identify potential biomarkers, we applied an UPLC-HDMS together with univariate and multivariate statistical analyses using plasma samples from patients with CKD of diverse etiologies (100 sera in discovery set and 120 sera in validation set) and two different rat models of CKD. Using comprehensive screening and validation workflow, we identified a panel of seven metabolites which were shared by all patients and animals regardless of the underlying cause of CKD. These included ricinoleic acid, stearic acid, cytosine, LPA(16:0), LPA(18:2), 3-methylhistidine, and argininic acid. The combination of these seven biomarkers enabled the discrimination of patients with CKD from healthy subjects with a sensitivity of 83.3% and a specificity of 96.7%. In addition, these biomarkers accurately reflected improvements in renal function in response to the therapeutic interventions. Our results indicated that the identified biomarkers may improve the diagnosis of CKD and provide a novel tool for monitoring of the progression of disease and response to treatment in CKD patients.
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Introduction
Chronic kidney disease (CKD) which leads to progressive loss of kidney function has become a primary public health problem involved with 11% of the U.S. population. 1 Individuals with CKD are at high risk for cardiovascular mortality and progression to end-stage renal disease (ESRD). 2, 3 One of the major hurdles toward improving clinical outcome of CKD has been the lack of diagnostic biomarkers at early stages of the disease.
Current clinical and laboratory methods for CKD diagnosis are limited to measurement of plasma urea and creatinine, urinary protein excretion, and measurement of creatinine clearance or the estimated glomerular filtration rate (eGFR). However, all of these methods are problematic to some extent. Serum creatinine is not an adequately sensitive marker for the early detection of kidney damage since it is affected by age, race, gender, muscle mass, total body weight and nutritional status. While being useful in mass screening for CKD, proteinuria and the decline in eGFR are relatively insensitive markers and have limited value in the detection of early phases of kidney injury. 4 Hence, more sensitive and cost-effective biomarkers are needed to identify the at-risk patients earlier in the disease process and to carefully monitor progression of CKD and its response to treatment in this vulnerable population.
Emerging platforms in the biomedical arena offer a new tool to identify novel biomarkers. Metabolomics is a new member of omics technologies that focuses on either qualitative or quantitative measurement of the dynamic multi-parametric metabolic response of living organisms to pathophysiological stimuli. It is rapidly emerging as a discovery tool for identification of the new diagnostic and prognostic biomarkers of human diseases. [5] [6] [7] Our previous studies have shown the usefulness of UPLC-HDMS-based metabolomics approach for diagnosis and evaluation of CKD. [8] [9] [10] We have found a series of metabolites which are significantly altered in CKD, reflecting metabolic dysfunction in the pathway of glycerophospholipid, fatty acid, amino acid, purine, taurine and choline metabolisms. However, no individual metabolites or combination of metabolites have been evaluated for their value as biomarkers for diagnosis and monitoring of the CKD progression and its response to therapeutic 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 5 controls, 30 CKD stages 4-5 patients, 30 CKD patients with enalapril treatment and 30 CKD patients with irbesartan treatment was collected for the validation of biomarkers. CKD+enalapril and CKD+irbesartan patients were orally administered enalapril (10 mg/day) and irbesartan (150 mg/day) for 8 weeks. CKD stages 4-5 were defined as eGFR < 29 ml/min/1.73 m 2 , MDRD-4 equation. We will refer to 'CKD stages 4-5' as 'CKD' all along the manuscript. Plasma was collected and stored at −80 °C until analysis.
Animal experiments.
Adenine-induced CKD model
Male Sprague-Dawley rats, weighing 200 ± 10 g were purchased from Fourth Military Medical University (Xi'an, China). The rats were randomly to divide into the following four groups (n=8): control, CKD, CKD+irbesartan and CKD+ergone groups. CKD, CKD+irbesartan and CKD+ergone groups received adenine dissolved in 1% (w/v) gum acacia solution (200 mg/kg body weight) by oral gavage once every day for three weeks. 8, 12 Control group received the same volume of gum acacia solution. CKD+irbesartan and CKD+ergone groups were orally administered irbesartan (20 mg/kg/day) and ergone (20 mg/kg/day) for six weeks starting 3 hours after adenine gastric gavage. All the rats were anesthetized with 10% urethane and plasma samples were collected by carotid artery cannula at week 6. Plasma was collected and stored at −80 °C until analysis. This study was approved by the Ethical Committee of Northwest University and studies were conducted in accordance with the Chinese national legislation and local guidelines.
5/6 nephrectomy CKD model
Male Sprague-Dawley rats (225-250 g) were fed regular rat chow and water ad libitum and randomly assigned to the control, CKD, CKD+enalapril and CKD+ RTA dh404 groups (n=8). The animals allocated to the CKD, CKD+enalapril and CKD+ RTA dh404 groups underwent 5/6 nephrectomy by surgical resection of the upper and lower thirds of left kidney, as described previously. 13 The animals allocated to the control group underwent sham operation. CKD+enalapril and CKD+ RTA dh404 groups were orally administered enalapril (10 mg/kg/day) and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 6 RTA dh404 (2 mg/kg/day) for 12 weeks starting immediately prior to surgery. The procedures were carried out under general anesthesia (50 mg/kg ip Nembutal) using strict hemostasis and aseptic techniques. All the rats were anesthetized with 10% urethane, and plasma samples were obtained by carotid artery cannula at week 12. Plasma was collected and stored at −80 °C until analysis.
Biochemical determination
Serum and urine biochemistry were analyzed as described in detail previously. 14 The measurements for each of the samples for biochemical parameters were replicated 3 times.
Renal histology and immunohistochemistry
H&E, PAS, Masson trichrome staining, TGF-β1, ED-1, PCNA and iNOS immunohistochemical staining were performed according to published methods. 9, 10, 15 The materials and methods of this section was described in detail in supplementary materials. The measurements for each of the samples were replicated 3 times.
Metabolomics
Plasma for metabonomics was prepared as described previously. 14 Metabolomics were performed on a Waters Acquity TM Ultra Performance LC system equipped with a Waters Xevo TM G2-S QTof MS. Chromatographic separation, mass spectrometry, data processing were described in the Supporting information.
Statistics
Fold changes from CKD group/control group and ROC curve was performed by Metaboanalysis 3.0. Differences between the means of the two groups were analyzed using Student's t-test and Mann-Whitney test by SPSS 19.0.
VIP was used to rank the contribution of each variable based on the PLS-DA model, and those variables with VIP > 1.0 are considered relevant for group discrimination. 16 The critical p-value was set at 0.05 for this study. Based on the Hochberg-Benjamini method, the resultant p values from Student's t-test were further adjusted by an FDR. The CKD patients exhibited hypertension, proteinuria, significant increase in plasma urea, creatinine, uric acid, and triglyceride concentrations, and significant reductions in serum albumin, red blood cell count and blood hemoglobin concentrations (Table 1) . Compared with the control group, rats in both CKD models exhibited significantly increased creatinine, urea, triglycerides and total cholesterol concentrations and significant reduction in creatinine clearance (Ccr) ( Table 2 ). As expected the 5/6 nephrectomized CKD rats showed significantly greater proteinuria and hyperlipidemia when compared with the CKD rats with adenine-induced chronic tubulointerstitial nephropathy. Physiologic parameters of animals showed in Table 3 .
Results
General data
Metabolomics data
Validation of UPLC-HDMS findings is described in detail in the Supplementary information. Metabolic profiling of plasma sample including CKD patients, adenine-induced CKD rats, and 5/6 nephrectomized rats was acquired using UPLC-HDMS in ESI + and ESI − modes. Since metabolites detected in both ESI + and ESI − modes complemented each other, data generated from ESI + and ESI − modes were combined to perform statistical analysis. As shown in Figure S1 , principal component analysis (PCA) and the partial least-square-discriminant analysis (PLS-DA) showed a clear intergroup separation in plasma metabolites from control group and CKD patients and between control rats and rats with adenine-induced CKD. For 5/6 nephrectomized rats, PCA showed a trend for intergroup separation and PLS-DA displayed a clear separation between control and CKD groups ( Figure S1 ). The PCA and PLS-DA results indicated significant alteration in plasma metabolic profiles in patients with CKD and rats with CKD of distinctly different etiologies. Differential metabolites contributing to the altered metabolic profiles of patients with CKD and rats with adenine-induced CKD and 5/6 nephrectomized CKD were identified according to the previously reported methods 17, 18 and summarized in Tables S1, S2 and S3 respectively.
They were selected using the VIP (variable importance in the projection) values (>1.0) combined with Student's t-test (p < 0.05) with a false discovery rate (FDR) < 0.05 and Mann-Whitney U test (p < 0.05).
We identified 71, 96 and 43 differential metabolites from patients with CKD, 5/6 nephrectomized CKD rats, and adenine-induced CKD rats respectively (Tables S1-S3) . We then applied heatmap based on the analysis of Pearson correlation coefficients to visualize the relative levels of the differential metabolites ( Figure S2 ). As shown in Figure 2A , 26 metabolites showed similar trends in the CKD patients and 5/6 nephrectomized CKD rats;
13 metabolites showed similar trends in CKD patients and adenine-induced CKD rats and 3 metabolites showed similar trends in CKD patients with both CKD animal models. Thus, these 36 differential metabolites (p < 0.05)
were selected as biomarker candidates of CKD. The distribution of these 36 metabolites across all specimens from CKD patients is presented in the z-score plots ( Figure 2B ). The heatmap of these 36 candidate biomarkers is shown in Figure 2C .
The significance analysis of microarrays (SAM) was used to select the most significant metabolites ( Figure   S3 ). A total of 17 metabolites, which were the most significant metabolites for the differentiation of the CKD from the control groups were retained in the candidate pool (Table 4) . Subsequently, the diagnostic potential of these candidates was evaluated. Receiver operating characteristic (ROC) curve was exploited based on the results of the area under the curve (AUC), the sensitivity, and specificity at the best cutoff points ( Figure 2D ). Table 4 shows the results of ROC analysis for the discovery set. As shown in Table 4 , 3-hydroxyhexadecanoic acid, MG(15:0), lipoyllysine, arachidic acid, creatinine, tryptophanol and docosapentaenoic acid were removed from the candidate pool because of the low AUC, sensitivity or specificity. Thus, a total of 10 metabolites were retained in the candidate pool. Figure 3 presents the relative contents of these 10 potential biomarkers across all groups. The concentrations of 12-ketodeoxycholic acid and indolelactic acid were significantly increased in CKD patients compared to control group but were significantly decreased in 5/6 nephrectomized CKD rats compared to the control rats. Similarly, the concentration of hypotaurine was significantly decreased in CKD patients compared to the control group but was significantly increased in rats with adenine-induced CKD compared to the control rats.
Therefore these three candidate biomarkers presented opposite trends on the effect of CKD in patients and rats and were removed from the candidate pool. Finally, hierarchical cluster analysis (HCA) was performed to reveal the correlation among the remaining seven candidates. These candidates were clustered into two groups in the light of their Pearson correlation coefficients ( Figure. 3A, I-II). Cluster I included two fatty acids (ricinoleic acid and stearic acid) and cytosine.
Cluster II consisted of two lipids [LPA(16:0) and LPA (18:2)], 3-methylhistidine and argininic acid.
Validation of Metabolic Biomarkers
The first step verification
Another independent set of plasma samples (30 patients and 30 healthy subjects) was collected and analyzed in the validation phase to validate the reliability of these seven candidates as biomarkers of CKD. As shown in Figure 4B , twenty-five out of thirty CKD patients were correctly grouped (83.3% sensitivity). Twenty-nine out of thirty healthy individuals were correctly grouped (96.7% specificity). Figure 4C and 4D shows the ROC curves of the individual biomarkers and the combination of the 7 biomarkers from CKD patients in validation phase.
The second step verification
A number of clinical and experimental animal studies have demonstrated that up-regulation of renin-angiotensin system are closely associated with progression of renal disease. 13, 19 Several clinical trials have shown that irbesartan (IRB) significantly slows the progression of diabetic nephropathy and non-diabetic advanced CKD. 20, 21 Ergosta-4,6,8(14),22-tetraen-3-one (ergone) is one of the bioactive steroids from Cordyceps sinensis. 22 Our previous study revealed that ergone were able to prevent progression of renal injury and subsequent renal fibrosis. 23, 24 To further validate the biomarker candidates, we tested whether administration of irbesartan and ergone can attenuate tubulointerstitial fibrosis and improve abnormalities of the identified biomarker candidates 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 10 irbesartan significantly decreased upregulation of 3-methylhistidine, argininic acid and partially reversed downregulation of cytosine. In addition irbesartan attenuated upregulation of LPA (18:2) however the difference did not reach statistical significance ( Figure 4G ). In contrast to irbesartan, ergone failed to reverse the adenine-induced changes of all the candidate biomarkers.
Enalapril is an angiotensin-converting-enzyme inhibitor widely used in CKD patients. 25 Oxidative stress and inflammation play a major role in the development and progression of CKD and are, in part, mediated by the impaired activation of the cytoprotective transcription factor, nuclear factor-erythroid-2-related factor 2 (Nrf2).
26
Protective effects of Nrf2 are proved by amelioration of oxidative stress, inflammation, and kidney diseases with administration of natural Nrf2 activators in animal models, 27, 28 and occurrence of autoimmune nephritis in Nrf2 knock out mice.
In fact administration of the synthetic triterpenoid RTA dh404
(2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid-9,11-dihydro-trifluoroethyl amide or CDDO-dhTFEA), a Nrf2 activator, has been shown to retard CKD progression in 5/6 nephrectomized rats. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 11 candidate biomarkers. They significantly decreased upregulation of LPA(16:0), LPA(18:2), 3-methylhistidine, and argininic acid and reversed downregulation of cytosine and ricinoleic acid ( Figure 4M ).
Discussion
In the present study, we used UPLC-HDMS-based metabolomic approach to profile plasma metabolites in order to identify potential common plasma biomarkers of CKD in rats with adenine-induced CKD and 5/6
nephrectomized CKD and in patients with CKD. wWe included samples from different animal models of CKD and patients with CKD of diverse etiologies in order to identify the biomarkers of CKD itself by excluding the impact of changes caused by the underlying cause of CKD.
The study was divided into two parts, including discovery and validation ( Figure 1) . In discovery phase, we applied a comprehensive workflow to identify novel biomarkers. In validation phase, we collected and analyzed another batch of plasma samples including including 30 controls, 30 CKD patients, 30 CKD patients with enalapril treatment and 30 CKD patients with irbesartan treatment to validate the reliability of these seven biomarker candidates. We used the same methods of sample pretreatment, instrumental detection, and data analysis. These seven biomarkers offered good diagnostic performances for discrimination of patients with CKD from healthy subjects with a sensitivity of 83.3%, a specificity of 96.7% ( Figure 4B ) and a AUC of 0.997 ( Figure   4D ). The results indicated that the seven biomarkers could be improved by the irbesartan, ergone, enalapril or RTA dh404 treatments ( Figure 4G , 4J, 4M). Therefore, collectively these metabolites represented satisfactory biomarkers for clinical diagnosis, monitoring of disease progression, and response to therapeutic interventions in CKD of diverse etiologies.
In an attempt to gain a deeper understanding of the identified biomarkers, we performed a systematic pathway analysis based on 36 significantly differential metabolites. As shown in Figure 5A , the CKD-associated metabolic perturbation involved pathways of glycerophospholipid, taurine, hypotaurine and fatty acid metabolism among others. Figure 5B shows the metabolic pathways of identified biomarkers. The present study showed a Page 11 of 27 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 12 clear increase in plasma 3-methylhistidine and argininic acid in CKD patients. Both of these compounds are among uremic toxins which have been implicated in progression of CKD and development of CKD-related complications. Earlier study has revealed a significant increase in plasma 3-methylhistidine in patients with stage 3-4 CKD, 30 confirming the results of the present study. In addition, using hemodialysis patients before and after correction of acidosis. 32 With the correction of the metabolic acidosis, they found the level of 3-methylhistidine was reduced significantly. The latter is considered a valid marker for skeletal muscle breakdown in humans. Thus, the marked elevation of plasma 3-methylhistidine reflects accelerated loss of muscle mass in patients with CKD. Argininic acid, a guanidine compound, is a urea derivative. Blood level of guanidine compounds rise as a result of excess dietary intake or impaired clearance by the kidneys. Blood concentration of argininic acid is significantly increased in uremic compared to the normal populations. 33 Our previous study demonstrated significant increase in plasma argininic acid in rats with adenine-induced CKD.
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These findings are consistent with the result of the present study.
Decreased plasma stearic acid and ricinoleic acid were observed in our patients with CKD. Abnormal fatty acid metabolism is closely related to CKD. Recent study show that dysfunction of fatty acid oxidation rather than intracellular lipid accumulation induces the development of renal fibrosis. 34 Stearic acid has been reported to be decreased in the plasma of CKD patients and decreased abundance of stearic acid, was associated with declining renal function. 35 Ricinoleic acid has been reported to be decreased in the plasma of in rats with adenine-induced CRF.
CKD is associated with accumulation of lipids in the renal tissue which is primarily due to tubular reabsorption of filtered lipid-bound proteins 36, 37 and impaired fatty acid oxidation and contributes to the pathogenesis of renal fibrosis. 31 Our CKD patients exhibited significant reduction of plasma stearic acid and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 13 ricinoleic acid levels. These findings are in accord with the results of the earlier studies which have shown reduced plasma stearic acid in CKD patients 32 and reduced plasma ricinoleic acid in CKD rats.
Lysophosphatidic acid (LPA) is a growth factor-like phospholipid. LPA has been known to regulate several cellular processes such as cell motility, proliferation, survival and differentiation. It is now recognized as not only an intermediate in synthesis of glycerophospholipids but also a mediator in the onset of renal fibrosis. 38 Plasma LPA(16:0) and LPA (18:2) levels were significantly increased in our CKD patients. This is consistent with our previous study which showed significant increase in plasma LPA concentration in CKD compared to the control rats. 10 LPA is produced by several enzymes including phospholipases A1/A2, lysophospholipase D/autotaxin, glycerol-phosphate acyltransferase, or monoacylglycerolkinase. 39 Therefore increased plasma LPA(16:0) and LPA(18:2) level in CKD patients may be due to increased expression and/or the activity of these enzymes .
Conclusions
In summary, we employed a UPLC-HDMS-based metabolomics method to identify a unifying plasma metabolic profile in CKD patients and animals with CKDs of distinctly different etiologies. We found a panel of 7 plasma metabolites based on the comprehensive screening and validation workflow. These metabolites were significantly altered in humans and animals with CKDs of diverse etiologies and as such represent reliable biomarkers of renal insufficiency independent of the underlying cause of renal disease. Table S1 . Differential plasma metabolites of patients between control and CKD group based on metabolomic profile in positive and negative ion modes. Table S2 . Differential plasma metabolites of adenine induced CKD rats between control and CKD group based on metabolomic profile in positive ion mode and negative ion modes. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 14 based on metabolomic profile in positive and negative ion modes. Control groups from patients.
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